United States

Mayne Pharma Group Ltd (MYX.AX)

MYX.AX on Australia Stock Exchange

18 Aug 2017
Change (% chg)

$-0.01 (-1.36%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low


Chart for MYX.AX


Mayne Pharma Group Limited is a specialty pharmaceutical company, which focuses on applying its drug delivery capability to commercialize branded and generic pharmaceuticals. The Company also provides contract development and manufacturing services. It operates in four segments: Generic Products (GPD), Specialty Brands (SBD),... (more)


Beta: 1.54
Market Cap(Mil.): $1,110.79
Shares Outstanding(Mil.): 1,532.12
Dividend: --
Yield (%): --


  MYX.AX Industry Sector
P/E (TTM): 10.17 31.45 32.56
EPS (TTM): 0.07 -- --
ROI: 8.05 15.33 14.89
ROE: 10.69 16.35 16.13

BRIEF-Mayne Pharma Group ‍sees FY17 underlying EBITDA of between A$212 mln to A$216 mln​

* Mayne pharma group ltd - ‍sees fy17 underlying ebitda of between a$212 - a$216 million​

Aug 07 2017

BRIEF-Mayne Pharma updates on FDA approval and first generic launch of Acticlate tablets

* U.S. FDA granted approval of ANDA for doxycycline hyclate immediate release (IR) tablets (75 MG AND 150 MG) in United States

Jun 14 2017

BRIEF-Mayne Pharma Group appoints Nick Freeman as new group CFO

* Mayne pharma appoints new group cfo and company secretary-myx.ax

Mar 08 2017

BRIEF-Mayne Pharma executes license and supply agreement for generic Nuvaring® in US

* Mayne Pharma executes license and supply agreement for Generic Nuvaring® in US

Feb 27 2017

BRIEF-Mayne Pharma Group HY revenue $294.8mln, up 132% on 1hfy16

* Hy reported net profit after tax of $72.7m, up 278% Source text for Eikon: Further company coverage:

Feb 23 2017

Earnings vs. Estimates